CA2116764C - Immunoreactive hepatitis c virus polypeptide compositions - Google Patents

Abstract

This invention relates generally to immunoreactive polypeptide compositions comprising hepatitis type C viral epitopes, methods of using the compositions in immunological applications, and materials and methods for making the compositions.

Description

WO 93/06126 i 6 ~ ~ ~ PCT/LS92/0%683 IM~IUNOREACTIYE HEPATITIS C VIRUS POLYPEPTIDE COMPOSITIONS
Technical Field This invention relates generally to immunoreactive polypeptide compositions, methods of using the compositions in immunological applications, and materials and methods for making the compositions.
Background The hepatitis C virus has been recently identified as the major causative agent of post=
transfusion Non-A, Non-H hepatitis (NANF~), as well as a significant cause of community-acquired NANBH.
Materials and methods foz obtaining the viral genomic sequences are known. See, e.g. PCT Publication Nos.
W089/04669, W090/11089 & W090/14436.
Molecular characterization of the HC'V genome indicates that it is a RNA molecule of positive polarity containing approximately 10,000 nucleotides that encodes a polyprotein of about 3011 amino acids. Several lines of evidence suggest that HC'V has a similar genetic organization to the viruses of the family Flaviviridae, which includes the flavi- and pestivirus. Like its pests- and flaviviral relatives. HC'V appears to encode a large polyprotein precursor from which individual viral proteins (both structural and non-structural) are processed.
RNA-containing viruses can have relatively high rates of spontaneous mutation, i.e., reportedly on the order of 10 3 to 10 4 per incorporated nucleotide.
Therefore, since heterogeneity and fluidity of genotype w0 93/06126 ~ ~ ~ ~ ~ PC~'/~~g92/07683 are common. in RNA viruses, there maybe multiple viral isolates, which may be virulent or avirulent, within the HCV species.
A number of different isolates of HCV have now been identified. The sequences of these isolates demonstrate the limited heterogeneity characteristic of RNA viruses.
Isolate HCV J1.1 is described in Rubo, Y. et al. (1989), Japan. Nucl. Acids Res. x:10367-10372;
Takeuchi, R. et al.(1990), Gene x:287-291; Takeuchi et al. (1990), J. Gen. Virol. 7:3027-3033; Takeuchi et al.
(1990), Nucl. Acids Res. x:4626.
The complete coding sequences plus the 5'- and 3'-terminal sequences of two independent isolates, "HCV-J" and "HR", are described by Rato et al. and Takamizawa et al, respectively. (Rato et al. (1990), Proc. Natl. Acad. Sci. USA x:9524-9528; Takamizawa et al (1991), J. Virol. ~x:1105-1113.) Other publications describing HCV isolates are the following;
~HCV-1": Choo et al (1990), Brit. Med.
Hull. x:423-441; Choo et al. (1991), Proc.
Natl. Acad. Sci. USA g,~:2451-2455; Han et al.
(1991), Proc. Natl. Acad. Sci. USA gg:1711-1715; European Patent Publication No. 318,216.
~HC-J1~ and ~HC-J4~: Okamoto et al.
(1991), Japan J. Bxp. Med. ~Q:167-177.
~HCT 18~, ~HCT 23~, ~Th~, ~HCT 27~, ~EC1"
aad ~BC10~: Weiner et al. (1991), Virol.
~,~Q: 842-848 .
~Pt-1~, ~HCV-Ri~ and ~HCV-R2~: Bnaanoto et al, There are two major types of hepatitis C
virus in Japan. Division of Gastroenterology, Departmeat of Interaal Medicine, Ranazawa Medical University, Japan.

'3' 211676 Clones "A", "C", "D" & "E": Tsukiyama-Rohara et al., A second group of hepatitis virus, in Virus Genes.
A typical approach to diagnostic and vaccine strategy is to focus on conserved viral domains. This approach, however, suffers from the disadvantage of ignoring important epitopes that may lie in variable domains.
It is an object of this invention to provide polypeptide compositions that are immunologically cross-reactive with multiple 8CV isolates, particularly with respect to heterogeneous domains of the virus.
Summary of the Invention According to an aspect of the present invention there exists an immunogenic polypeptide composition which comprises at least two HCV amino acid sequences, each HCV
sequence comprising at least one epitope within a variable domain of an HCV envelope protein, wherein the variable domain regions of the amino acid sequences are heterogeneous with each other and are derived from distinct HCV isolates.
According to another aspect of the present invention there exists a method of detecting antibodies to HCV within a biological sample which comprises (a) providing a biological sample suspected of containing antibodies to multiple strains of HCV; (b) providing a polypeptide reagent; (c) reacting the biological sample of (a) with the polypeptide reagent of (b) under conditions which allow the formation of antigen-antibody complexes; and (d) detecting the formation of complexes formed between the antigen of (a) and the antibodies of the biological sample of (b), if any; characterized in ~A

that as a polypeptide reagent .it contains a immunoreactive composition which comprises at least two HCV amino acid sequences, each HCV sequence comprising at least one epitope within a variable domain of an HCV
envelope protein, wherein the variable domain regions of the amino acid sequences are heterogeneous with each other and are derived from distinct HCV isolates.
According to yet another aspect of the present invention there exists a DNA molecule encoding a polypeptide which comprises two heterogeneous amino acid sequences from the same variable domain of distinct HCV
icnlatac ...
r -. 21 16764 Brief Descrirti~n of the Fi Figure 1 schematically shows the genetic organization of the HCV genome.
Figure 2 shows a co~npazison of the deduced amino acid sequences of the E1 protein encoded by group I
and group II HCV isolates.
w.A'~.
Figure 3 shows a comparison of the~amino acid sequences of the putative E2/NS1 region of HCV isolates.
Figure 4 are graphs showing the antigenicity profiles for the amino-terminal region of the putative WO 93/06126 - 6 - ~ 116 7 G 4 P~/l'S92/07683 HCV E2/NS1 protein (amino acids 384-420), and the gp 120 V3 hypervariable region of HIV-1.
Figure 5 shows a series of graphs which give the percentage probabilities that a given residue from the amino-terminal region of HCV E2/NS1 protein (amino acids 384 to 420) will be found in either alpha-helix, beta-sheet or beta-turn secondary structural motif.
Figure 6 are bar graphs showing the reactivity of antibodies in the plasma from HCV 18 (panels A-C) or Th (Panels D-f) with overlapping biotinylated 8mer peptides derived from amino acids 384 to 415 or 416 of HCV isolates HCT 18 (A, D), Th (H, E) and HCV J1 (C, F), respectively.
Figure 7 shows the deduced amino acid sequences of two regions of the E2/NS1 polypeptide, amino acids 384-414 and 547-647, given for the Q1 and Q3 isolates.
Figure 8A shows the deduced amino acid sequences of isolates HCV J1.1 and J1.2 from amino acids 384 to 647. Figure 8B shows the deduced amino acid sequences of isolates HCT27 and HCVE1 from amino acids 384 to 651.
Figure 9 shows the entire polyprotein sequence of isolate HCV-1.
Modes of Practicing the Invention The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recoanbiaaat DNA, and iamunology, which are within the skill of the art. Such techniques are explained fully in the literature. ~ e.g., Maniatis, Fitsch & Sambrook, MOLBCULAR CLONING; A LABORATORY MANUAL (2nd ed. 1989);
DNA CLONING, VOLUMBS I AND II (D.N Glover ed. 1985);
OLIGONUCL80TID8 SYNTHESIS. (M. J. Gait ed, 1984); NUCLEIC
ACID HYBRIDIZATION (H. D. Hames & S.J. Higgins eds. 1984);

' ' ~ ~ WO 93/06126 ~ ~ ~ ~ PCT/t_S92/07l>83 _ 7 ..
TRANSCRIPTION AND TRANSLATION (H. D. games & S.J. Higgins eds. 1984); ANIMAL CELL CULTURE (R. I. Freshney ed. 1986);
IMMOBILIZED CELLS AND ENZYMES (IRL Press, 1986); H.
Perbal, A PRACTICAL GUIDE TO MOLECULAR CLONING (1984);
the series, METHODS IN ENZYMOLOGY (Academic Press, Inc.);
GENE TRANSFER VECTORS FOR MAMMALIAN CELLS (J. H. Miller and M.P.~ Calos eds. 1987, Cold Spring Harbor Laboratory), Methods in Enzymology Vol. 154 and Vol. 155 (Wu and Grossman, and Wu, eds., respectively), Mayer and Walker, eds. (1987), IMMUNOCHEMICAL METHODS IN CELL AND MOLECULAR
BIOLOGY (Academic Press, London), Scopes, (1987), PROTEIN
PURIFICATION: PRINCIPLES AND PRACTICE, Second Edition (Springer-Verlag, N.Y.), and HANDHOOR OF EXPERIMENTAL IM-MUNOLOGY, VOLUMES I-IV (D.M. Weir and C. C. Hlackwell eds 1986); IMMUNOASSAY: A PRACTICAL GUIDE (D.W. Chan ed.
1987). All patents, patent applications, and publica-tions mentioned herein, both above and below, are incorporated by reference herein.
HCV is a new member of the Family Flaviviridae which includes the pestiviruses (Hog Cholera Virus and Bovine Viral Diarrhea Virus) and the Flaviviruses, examples of which are Dengue and Yellow Fever Virus. A
scheme of the genetic organization of HCV is shown in Figure 1. Similar to the flavi- and pestiviruses, HCv appears to encode a basic polypeptide domain ("C") at the N-terminus of the viral polyprotein followed by two glycoprotein domains ("E1", "82/NS1"), upstream of the nonstructural genes NS2 through NSS. The amino acid coordinates of the putative protein domains are shown in Table 1.

w0 93/06126 2116' 6 4 P~/~S92/0~68s Table 1. The Putative Protein Domains in HCV
a.a. coordinates (aD~roxima ) protein 192 - 383 El As discussed above, a number of HCV isolates have been identified. Comparative sequence analysis of complete and partial HCV sequences indicates that based upon homology at the nucleotide and amino acid levels, HCV isolates can be broadly snub-divided into at least three basic groups (Table 2). See Houghton et al., (1991) Hepatology ~,g:381-388. However, only partial sequence is available for the isolates in group III.
Therefore, when the sequences of these isolates are more defined, one or more of these isolates may deserve separation into a different group, including a potential fourth group. Table 3 shows the sequence homologies between individual viral proteins of different HCV
isolates as deduced from their nucleotide sequences. It can be seen that the proteins of the same virus group exhibit greater sequence aimi.larity than the same proteins encoded by different virus groups (Table 3).
One exception to this is the nucleocapsid protein that is highly conserved among all group I sad II viral ieo~lates sequences to date. (In Table 3, the symbol N/A signifies that the sequences were not available for comparison.) For purposes of the present invention, therefore, group I
isolates can be defined as those isolates having their viral proteins, particularly F:1 and FZ/NS1 proteins, about 90~ homologous or more apt the amino acid level to WO 93/06126 2116 7 f 4 P~/l'S92/0"683 _g..
the 'isolates classified as group I herein. Group II is defined in an analogous manner. Future groups can likewise be defined in teens of viral protein homology to a prototype isolate. Subgroups can also be defined by homology in limited proteins, such as the E1, E2/NS1 or NS2 proteins, or by simply higher levels of homology.
Table 2. ~iass~fication of hey~atitis C viral gnome ~Nn seauences into three basic arouos.
HCV II HCV IIII HCV III
HCV-1 HCV-J1.1 Clones A,C,D&E
HC-J1 HC-J4 HCV-R2 (a&b) Th HCV-K1 EC1 ' Pt-1 Table 3. Amino Acid Homologies (~) Between Viral Proteins Different Encoded HCV
by Isolates E~ E.?~ ~ N~3.

T comfl ared to III N/A N/A N/A N/A 86 ?6-80 71-74 TT ~o mflared to TTT c ompare o t -lo- 2 1 16 7 6 4 va It is noteworthy that the putative viral envelope proteins encoded by the E1 and E2/NS1 genes show substantial amino acid sequence variation between groups I and II. Only NS2 exhibits a greater degree of heterogeneity, while the C, NS3, NS4 and NS5 proteins all show greater sequence consezvation between groups. The sequence variation observed in the putative virion envelope proteins between groups I and II reflects a characteristic segregation of amino acids between the two groups. An example of this is showrn in Figure 2 where the sequence of the E1 gene product is compared between viruses of groups I and II. The E1 amino acid sequences deduced from nucleotide sequences of HCV groups I and II
are shown. In the figure, the horizontal bars indicate sequence identity with HCV-1. The asterisks indicate group-specific segregation of amino acids; the group-specific residues can be clearly identified. Group I
sequences are HCV-1, HCT18, HCT23, HCT27, and HC-J1.
Group II sequences are HC-J4, HCV-J, HCV J1.1, and BK.
Such group-specific segregation of amino acids is also present in other gene products including gp72 encoded by the E2/NS1 gene. Figure 3 shows the comparative amino acid sequence of the putative E2/NS1 region of HCV
isolates which segregate as group I and group II. The latter protein also contains an N-terminal hypenrariable region ("HV") of about 30 amino acids that shows large variation between nearly all isolates. See Weiner et al.
(1991), supra. This region occurs between amino acids 384 to 414, using the amino acid numbering system of HCV-1.
The putative HCV envelope glycoprotein E2/NS1 may correspond to the gp53(BVDV)/gp55 (Hog Cholera Virus) envelope polypeptide of the pestiviruses and the NS1 of ~A

w0 93/06126 ~ ~ ~ ~ ~ PCT/LS92/07683 the flaviviruses, both of which. confer protective immunity in hosts vaccinated with these polypeptides.
Striking similarities between the hype nrariable region ("HV") and HIV-1 gp120 V3 domains with respect to degree of sequence variation, the predictive effect of amino acid changes on putative antibody binding in addition to the lack of defined secondary structure suggest that the HV domain encodes neutralizing antibodies.
The immunogenicity of the domain is shown by antibody epitope mapping experiments, described in the Examples. The results of these studies suggest that in addition to the three major groups of HCV, HV specific sub-groups also exist.
Analysis of biological samples from individuals with HCV induced NANHH indicate that individuals may be carrying two or more HCV variants simultaneously .- Two co-existing HV variants were found is the plasma of one individual, J1. In addition, partial sequencing of the gene of an individual vYith chronic NANBH, who had intermittent flares of hepatitis, revealed that the individual, Q, was infected with two HCV variants (Q1 or Q3). Each variant was associated with only one episode of the disease. An ELISA using a Q1 or Q3 specific 25~ peptide (amino acids 396-407) showed that Q developed an antibody response to the Q1 peptide but not the corresponding Q3 peptide, suggesting that Q's recnidesceace of disease was due to the appearance of an FiV variant. The presence of antibodies to the Q1 peptide but lack of humoral ia~nune response to the Q3 peptide during the second episode of disease suggest that variation in the HV doanain may result fry the pressure of iaarune selection. Amino acids 396-407 appear to be subject to the greatest selective pressure in the Hv domain. These findings support the thesis that high WO 93/06126 2 ~ ~ s 7 s ~ PCT/1.S92/07683 _ 12 ..
levels of chronicity associated with.the disease might be due to an inadequate immunological host response to HCv infection and/or effective viral mechanisms of immunological evasion. Moreover, they point to the E2/NS1 HV region as a genetic region involved in a viral escape mechanism and/or an inadequate immunological response ~ mechanism ( s ) .
As discussed above, there are several variant regions within the HCV genome. One or more of these regions are most likely involved in a viral escape mechanism and/or an inadequate immunological response mechanism. Therefore, it is desirable to include in compositions for treatment of HCV polypeptides which would induce an immunogenic response to these variants.
In that the E1 and E2/NS1 regions of the genome encode putative envelope type polypeptides, these regions would be of particular interest with respect to immunogenicity. Thus, these regions are amongst those to which it would be particularly desirable to induce and/or increase an immune response to protect an individual against HCV infection, and to aid in the prevention of chronic recurrence of the disease in infected individuals. In addition, these regions would be amongst those from which it would be desirable to detect HCV
variants which are arising during the course of infection; as well as super- or co-infection by two or more variants.
The present invention describes compositions sad methods for treating individuals to prevent HCV
infections, and particularly chronic HCV infections. In addition, it describes compositions and methods for detecting the presence of anti-FiCV antibodies in biological samples. This latter arethod is particularly useful in identifying anti-HCV antibodies generated in response to immunologically distinct HCV epitopes. This WO 93/06126 2116' ~ 4 PCT/1.~S92/07683 method can also be used to study the evolution of multiple variants of HCV within an infected individual.
In the discussion of the invention, the following definitions are applicable.
The term ~polypeptide" refers to a polymer of - amino acids and does not refer to a specific length of the product; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. This term also does not refer to or exclude post-expression modifications of the polypeptide, for example, glycosylations, acetyiations, phosphorylations and the like. Included within the definition are, for example, polypeptides containing one or more analogues of an amino acid (including, for example, unnatural amino acids, etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring.
Jars used herein, A is ~substantially isolated"
from H when the weight of A is at least about 70~, more preferably at least about 80~, and most preferably at least about 90~ of the combined weights of A and H. The polypeptide compositions of the present invention are preferably substantially free of human or other primate tissue (including blood, serum, cell lysate, cell organelles, cellular proteins, etc.) and cell culture medium.
A ~recombinant polyaucleotide~ intends a polynucleotide of genomic, cDNA, aemisynthetic, or synthetic origin which, by virtue of ite origin or manipulatioa: (1) is not associated with all or a portion of a polynucleotide with which it is associated in nature, (2) is linked to a polynucleotide other than that to which it is linked in nature, or (3) does not occur in nature.

N'O 93/06126 21 i ~ 7 ~ ,~ PCT/ l'S92/0 % 683 A "polynucleotide" is,a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. This term refers only to the primary structure of the molecule. Thus, this term includes double- and single-stranded DNA and RNA. It also includes known types of modifications, for example, labels which are known in the art, methylation, "caps", substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as, for example, those with uncharged linkages (e. g., phosphorothioates, phosphorodithioates, etc.), those containing pendant moieties, such as, for example proteins (including for e.g., nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc.),those with intercalators (e. g., acridine, psoralen, etc.), those containing chelators (e.g.,metals, radioactive metals, etc.), those containing alkylators, those with modified linkages (e. g., alpha anomeric nucleic acids, etc.), as well as unmodified forms of the polynucleotide.
"Recombinant host cells", "host cells", "cells", "cell lines", "cell cultures", and other such terms denoting microorganisms or higher eukaryotic cell lines cultured as unicellular entities refer to cells which can be or have been, used as recipients for a recombinant vector or other transfer polynucleotide, and include the progeny of the original cell which has been transfected. It is understood that the progeny of a single parental cell may not necessarily be completely identical in morphology or in genamic or total DNA
complement as the original parent, due to natural, accideatal, or deliberate mutation.
A ~replicon~ is any genetic element, e.g., a plaamid, a chromosome, a virus, a cosmid, etc., that behaves as an autonomous unit of polynucleotide ' ~ WO 93/06126 ~ ~ i7 ~ PCT/l.'S92/0%683 _lc~_ replication within a cell; i.e., capable of replication under its own control.
A "vector" is a replicon further comprising sequences providing replication and/or expression of the open reading frame.
"Control sequence" refers to polynucleotide sequences which are necessary to effect the expression of coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and tezminators; in eukaryotes, generally, such control sequences include promoters, terminators and, in some instances, enhancers. The term "control sequences" is intended to include, at a minimum, all components whose presence is necessary for expression, and may also include additional components whose presence is advantageous, for example, leader sequences which govern secretion.
A "promoter" is a nucleotide sequence which is comprised of consensus sequences which allow the binding of RNA polymerase to the DNA template in a manner such that mRNA production initiates at the normal transcription initiation site for the adjacent structural gene.
~Operably linked" refers to a juxtaposition wherein the components eo described are in a relationship permitting them to functioa in their intended manner. A
control sequence ~operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.
An "open reading frame" (ORF) is a region of a polynucleotide sequence which encodes a polypeptide; this H'O 93/06126 ~ ~ ~ ~ ~ PCT/L'S92/0'683 -lt;-region may represent a portion of a coding sequence or a total coding sequence.
A "coding sequence" is a polynucleotide sequence which is transcribed into mRNA and/or translated into a polypeptide when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are detezmined by a translation start codon at the 5'-terminus and a translation stop codon at the 3'-terminus. A coding sequence can include but is not limited to mRNA, DNA (including cDNA), and recombinant polynucleotide sequences.
As used herein, "epitope" or ~antigenic determinant".means an amino acid sequence that is immunoreactive. Generally an epitope consists of at least 3 to 5 amino acids, and more usually, consists of at least about 8, or even about 10 amino acids. As used herein, an epitope of a designated polypeptide denotes epitopes with the same amigo acid sequence as the epitope in the designated polypeptide, and immunologic equivalents thereof.
An "antigen" is a polypeptide containing one or more epitopes.
"Immunogenic" means the ability to elicit a cellular and/or humoral immune response. An immunogenic response may be elicited by immunoreactive polypeptides alone, or may require the presence of a carrier in the presence or absence of an adjuvant.
"Ia~nunoreactive~ refers to (1> the ability to bind ia~unologically to an antibody and/or to a lymphocyte antigen receptor or (2) the ability to be iaacninogeaic .
An "antibody" is any immunoglobulin, including antibodies sad fragments thereof, that binds a specific epitope. The term encompasee~, ink ~, polyclonal, monoclonal, and chimeric antibodies. Examples of ' ' - ~ WO 93/06126 6 I~ PCT/hS92/07683 chimeric antibodies are discussed in U.S. Patent Nos.

4,816,397 and 4,816,567.
An "antigen set" is defined 'as a composition consisting of a plurality of substantially identical polypeptides, wherein the polypeptides are comprised of an amino acid sequence of one defined epitope~.
"Substantially identical polypeptides" means polypeptides that are identical with the exception of variation limited to the typical range of sequence or size variation attributable to the polypeptide's method of production; e.g., recombinant expression, chemical synthesis, tissue culture, etc. This variation does not alter the desired functional property of a composition of substantially identical polypeptides; e.g., the composition behaves immunologically as a composition of identical polypeptides. The variations may be due to, for example, alterations resulting from the secretory process during transport of the polypeptide, less than 100 efficiency in chemical synthesis, etc.
As used herein, a "variable domain" or "VD~ of a viral protein is a domain that demonstrates a consistent pattern of amino acid variation between at least two HCV isolates or subpopulatioas. Preferably, the domain contains at least one epitope. Variable domains can vary from isolate to isolate by as little as 1 amino acid change. These isolates can be from the same or different HCV groups) or subgroup(s). Variable domains can be readily identified through sequence composition among isolates, and examples of these techniques are described below. For the purposes of describing the present invention, variable daanains will be defined with respect to the amino acid number of the polyprotein encoded by the geaa~ne of HCV-1 as shown in Figure 9, with the initiator methionine being designated position 1. The corresponding variable domain in another WO 93/06126 ~ ~ ~ ~ PCT/ ~ S92/07683 HCV isolate is determined by aligning the two isolates sequences in a manner the brings the consezved domains outside any variable domain irato maximum alignment, This can be performed with any of a number of computer software packages, such as ALIGN 1.0, available from the University of Virginia, Department of Biochemistry (Attn:
Dr. William R. Pearson). ~g Pearson et al., (1988) Proc. Natl. Acad. Sci. USA g~:2444-2448. It is to be understood that the amino acid numbers given for a particular variable domain are somewhat subjective and a matter of choice. Thus, the beginning and end of variable domains should be understood to be approximate and to include overlapping domains or subdomains, unless otherwise indicated.
An epitope is the "immunologic equivalent" of another epitope in a designated polypeptide when it cross-reacts with antibodies which bind immunologically to the epitope in the designated polypeptide.
Epitopes typically are mapped to comprise at least about five amino acids, sometimes at least about 8 amino acids, and even about 10 or more amino acids.
The amino acid sequence comprising the HCV
epitope may be linked to another polypeptide (e.g., a carrier protein), either by covalent attachment or by expressing a fused polynucleotide to fozin a fusion protein. If desired, one may insert or attach multiple repeats of the epitope, and/or incorporate a variety of epitopes. The carrier protein may be derived from any source, but will generally be a relatively large, immunogenic protein such as HSA, KLH, or the like. If desired, one may employ a substaatially full-length HCv protein as the carrier, multiplying the number of immunogenic epitopes. Alternatively, the amino acid sequence from the HCV epitope may be linked at the amino terminus aad/or carboxy terminus to a non-HCV amigo acid WO 93/06126 6 ~ ~ ~ PCT/ l'S92/07683 sequence, thus the polypeptide would be a "fusion polypeptide". Analogous types of polypeptides may be constructed using epitopes from other designated viral proteins.
A "variant" of a designated polypeptide refers to a polypeptide in which the amino acid sequence of the designated polypeptide has been altered by the deletion, substitution, addition or rearrangement of one or more amino acids in the sequence. Methods by which variants occur (for example, by recombination) or are made (for example, by site directed mutageneais) are known in the art.
"Transformation" refers to the insertion of an exogenous polynucleotide into a host cell, irrespective of the method used for the insertion, for example, direct uptake, transduction (including viral infection), f-mating or electroporation. The exogenous polynucleotide may be maintained as a non-integrated vector, for example, a plasmid or viral geno~ne, or alternatively, may be integrated into the host genome.
An "individual" refers to a vertebrate, particularly a member of a maimnalian species, and includes but is not limited to rodents (e. g., mice, rats, hamsters, guinea pigs), rabbits, goats, pigs, cattle, sheep, and primates (e. g., chimpanzees, African Green Monkeys, babooas, orangutans, and humans).
As used herein, "treatment" refers to any of (i) the prevention of infection or reinfection, as in a traditional vaccine, (ii) the reduction or elimination of symptoms, and (iii) the substantial or complete elimination of the vines. Treatment may be effected prophylactically (prior to infection) or therapeutically (following infection) .
The term ~effective amount" refers to an amount of epitope-bearing polypeptide sufficient to induce an WO 93/06126 s ~ ~ 4 PCT/1592/0?683 immunogenic response in the individual to which it is administered, or to otherwise detectably immunoreact in its intended system (e.g., immunoassay). Preferably, the effective amount is sufficient to effect treatment, as defined above. The exact amount necessary will vary from application. For vaccine applications or in the generation of polyclonal antiserum/antibodies, for example, the effective amount may vary depending on the species, age, and general condition of the individual, the severity of the condition being treated, the particular polypeptide selected and its mode of administration, etc. Zt is also believed that effective amounts will be found within a relatively large, non-critical range. An appropriate effective amount can be readily determined using only routine experimentation.
As used herein, a "biological sample" refers to a sample of tissue or fluid isolated from an individual, including but not limited to, for example, plasma, serum, spinal fluid, lymph fluid, the external sections of the skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, milk, blood Bells, tumors, organs, biopsies and also samples of ~ vitro cell culture constituents (including but not limited to conditioned medium resulting from the growth of cells in cell culture medium, e.g., Mab producing myeloma cells, recombinant cells, and cell components).
The i~nuaoreactive polypeptide compositions of the present invention comprise a mixture of isolate- or group-specific epitopes from at least one I;CV VD. Thus, there will be present at least two heterogeneous amino acid sequences each defining an epitope found in distinct HCV isolates located in the same or substantially same physical location in an IiCV protein; i.e. each sequence maps to the same location within the HCV
genome/polypeptide. Since the sequences are ' ' ~ ~ WO 93/06126 ~ ~ ~ PCT/l'S92/0%683 heterogeneous, the location is referred to as a variable domain (VD) .
To better understand the invention, first the individual amino acid sequences that make up the compositions of the invention will be explained. Then the plurality of such sequences which are found in the compositions of the present invention will be discussed.
The amino acid sequence that characterizes the polypeptides of the present invention have a basic structure as follows:
Lr-Z-,L'y. (I) Z represents the amino acid sequence from a region of a protein from.a selected HCV isolate, where the region comprises at least one variable domain and the variable domain comprises at least one epitope. L and L' are non-HCV amino acid sequences or HCV amino acid sequences that do not contain a variable domain, and which can be the same or different. y and y' are 0 or 1 and can be the same or different. Thus, formula I represents an amino acid sequence comprising the sequence of an HCV VD, wherein the vD comprises an epitope.
As discussed above, the epitope(s) in Z will usually comprise a minimum of about 5 amino acids, more typically a minimum of about 8 amino acids, acid even more typically a minimum of about 10 amino acids.
The variable domain of Z can comprise more than one epitope. The variable domain of Z is at least as big as the combined sequences of the epitopes present, thus making it typically a minimum of about 5 amino acids when a single epitope fs present. Since epitopes can overlap, the minimum amino acid sequence for combined epitopes in ' the variable domain may be less than the sum of the individual epitopes' sequences.
Z is the amino acid sequence of an HCV isolate comprising the above-described VD. Thus, the minimum WO 93/06126 2116 7 G 4 P~/~~592/07683 size of Z is the minimum size of the VD. Z can comprise more HCV amino acid sequence than just the VD, and can further comprise more than one VD. The maximum size of Z
is not critical, but obviously cannot exceed the length of the entire HCV polyprotein. Typically, however, Z
will be the sequence of an entire HCV protein (particularly E1, E2/NS1, NS2, NS3, NS4 and NS5) or, even more typically, a fragment of such an HCV protein. Thus, Z will preferably range from a minimum of about 5 amino acids (more preferably about 8 or about 10 amino acids minimum) to a maximum of about 1100 amino acids (more preferably a maximum of about 500, more preferably a maximum of about 400 or even more preferably a maximum of about 200 amino acids maximum). More usually, the polypeptide of formula I and/or Z, when prepared by, e.g., chemical synthesis, is a maximum of about 50 amino acids, more typically a maximum of about 40 amino acids, and even more typically a maximum of about 30 amino acids.
The non-HC'V amino acid sequences, L and L', if present, can constitute any of a number types of such sequences. For example, L and L' can represent non-HCV
sequences to which Z is fused to facilitate recombinant expression (e. g., beta-galactosidase, superoxide diamutase, invertase, alpha-factor, TPA leader, etc.), as discussed below. Alternatively, L and L' can represent epitopes of other pathogens, such as hepatitis B virus, 9ordetella pertussis, tetanus toxoid, diphtheria, etc., to provide coenpositioas that are imnunoreactive relative to a number these other pathogens. L and L' can be amino acid sequences that facilitate attachment to solid supports during peptide synthesis, immunoassay supports, vaccine carrier proteins, etc. In fact, L and L' can even comprise one or more superfluous amino acids with no functional advantage. There is no critical maximum size . . ' WO 93/06126 2116 7 6 4 PCT/(.~S92/07683 for L or L', the length being generally governed by the desired function. Typically, L and L' will each be a maximum of about 2000 amino acids, more typically a maximum of about 1000 amino acids. The majority of L and L' sequences with useful properties will be a maximum of about 500 amino acids. It is desirable, of course, to select D and L' so as to not block the immunoreactivity of Z.
The composition of polypeptides provided according to the present invention are characterized by the presence (in an effective amount for immunoreactivity) within the composition of at least two amino acid sequences defined as follows by formulas II
and III, respectively:
Ly-Zi-L'r. (II) Ly - Zi - L' r. ( I I I ) L, L', y and y' are deffined as above, as well as independently defined for each of formulas II and III.
Z, and Zz are each HCV amino acid sequences as defined for Z above encompassing the same variable domain (i.e., physical location), but derived from different HCV
isolates having between them at least one heterogeneous epitope in the common variable domain of Z, and Zz. As an illustrative example, an amino acid sequence according to formula II could have as Z, a fragment the hypezvariable domain spanning amino acids 384-414 of isolate HCV-1 (or more particularly 396-407 or 396-408), while Z= is the analogous fragmeat from isolate HCV-J1.1. These two - isolates are heterogeneous in this domain, the amino acid sequences of the epitopes varying significantly.
It is to be understood that the compositions of the present iavention may comprise more than just two discrete amigo acid sequences according to for:aula I, and that the Z sequences may be divided into groups encompassing different variable do~naias. For example, a WO 93/06126 ~ ~ ~ ~ ~ ~ PCT/1 S92/07683 composition according to the present invention could comprise a group of HCV sequences (with amino acid sequences according to formula I) encompassing the hypervariable domain at amino acids 384-411 from isolates HCV-1, HCV-J1.1, HC-Jl, HC-J4, etc. The composition could also comprise an additional group of HCV sequences (within amino acid,sequences according to formula I) encompassing the variable domain at amino acids 215-255 also from isolates HCV-1, HCV-J1.1, HC-J1, HC-J4, etc.
Within the context of the compositions of the present invention, therefore, the sequence of formula I can be further defined as follows:
SVo ( IV ) V represents an amino acid sequence comprising the sequence of an HCV variable domain, wherein the variable domain comprises at least one epitope; i.e., formula I.
S and n are integers of 1 or greater. S represents a particular variable domain, and n represents a particular isolate. For example, S=1 could represent the variable domain at amino acids 384-411; S=2 could represent the variable domain at amino acids 215-255; and n=1, 2, 3 and 4 could represent isolates HCV-1, HCV-J1.1, HC-J1 and HC-J4, respectively. Thus, the two groups of sequences discussed above could be represented by:
Group 1: 1V" 1V=, iV~ & 1V, Group 2: 2V,, 2V=, 2Vf & 2V, There are at least two distinct sequences of formula IV is the compositions according to the present invention; i.e., the composition contains two different sequences according to formula IV where the values for S
and or n are different. For example, at least iV, and 1v, are present, or at least iV, and 2V= are present, or at least 1V, and 2V, are present .
The distinct sequences falling within formula IV are present iri the composition either on the same or ' ' WO 93/06126 ~ 21 I ~ 7 ~ ~ P~/l'S92/07683 different polypeptide molecules. Using the minimum combination of iV, and iVi to illustrate, these two sequences could be present in the same polypeptide molecule (e. g., lV,-iVz) or in separate molecules. This feature of the compositions of the present invention can be desczibed as compositions of polypeptides as follows:
' Rf- (SV,)=-R'~. (V) wherein S, V and n are as defined above: R and R' are amino acid sequences of about 1-2000 amino acids, and are the same or different; r and r' are 0 or 1, and are the same or different; x is an integer ~ 1; n is independently selected for each x; and with the proviso that amino acid sequences are present in the composition representing a combination selected from the group consisting of (i) iV, and iV=, (ii) iV, and 2V~, and (iii) 1V, and 2V,. In embodiments where the distinct sequences of formula IV are in different polypeptides, x can be 1, although it can still be ~1 if de:fired; e.g., a mixture of polypeptides iV,-iVz and iVl-2V=. When x is 1, r and r' are preferably both 0 to avoid redundancy with Ly and L'r., since V Can De aescriDea ay in a pre=errea embodiment by formula I. When x is ~1, the combined lengths of R and the adjacent L, and of R' and the adjacent L', are preferably no more than the typical ~~ lengths described above for L and L'.
The selection of the FiCV amino acid sequences included within the distinct V sequences of the coanpositions will depend upon the intended application of the sequeaces and is within the skill of the art in view of the present disclosure. First, it should be appreciated that the HCV epitopes of concern to the present inveation can be broken dower into two types. The first type of epitopes are those that are ~group-specific~; i.e., the corresponding epitopes in all or WO 93/06126 2116 7 6 4 P~/'592/07683 -26~-substantially all isolates within an HCV isolate group are immunologically cross-reactive with each other, but not with the corresponding epitopes of substantially all the isolates of another group. Preferably, the epitopes in a group-specific class are substantially conserved within the group, but not between or among.the groups.
The second type of epitopes are those that are "isolate-specific"; i.e., the epitope is immunologically cross-reactive with substantially identical isolates, and is not cross-reactive with all or substantially all distinct isolates.
These group- and isolate-specific epitopes can be readily identified in view of the present disclosure.
First, the sequences of several HCV isolates is compared, as described herein, and areas of sequence heterogeneity identified. The pattern of heterogeneity usually indicates group or isolate specificity. If an identified area is knows to co~npriae one or more epitopes, then a sequence of sufficient size to include the desired epitope(s) is selected to as an variable domain that may be included in the compositions of the present invention.
If the immunoreactivity of a given heterogeneous area is not known, peptides representing the sequences found in that area of the various HCV isolates can be prepared and screened. Screening can include, but is~not limited too, iaQminoassays with various sources of anti-HCV antibody (e.g., patient serum, neutralizing Mabe, etc.) or generatioa of antibody sad testing the ability of such antibody to neutralize virus in vitro. Alternatively, the loci of epitopes identified is a screening protocol, such as that described belowr caa be examined for heterogeneity among various isolates and the immunological properties of correspoadiag heterogeneous sequence' screened.

For vaccine applications, it is believed that variable domains from the E1 and/or E2/NSl domains will be of particular interest. In particular, an E1 variable domain within amino acids 215-255 (see Figure 2), and an E2/NS1 variable domain within amino acids 384-414 (see Figure 3), have been identified as being important immunoreactive domains. The preliminary evidence suggests that one or both of these domains may be loci of heterogeneity responsible for escape mutants, leading to chronic HCV infections. Thus, polypeptide compositions as described above where the variable domains) in V are one or both of these variable domains are particularly preferred. Furthermore, the polypeptide compositions of the present invention, while particularly concerned with the generally linear epitopes in the variable domains, may also include conformational epitopea. For example, the composition can be comprised of a mixture of recombinant E1 and/or E2/NS1 proteins (exhibiting the variable domains of different. isolates) expressed in a recombinant system (e. g., insect or mammalian cells) that maintains conformational epit.opes either inside or outside the variable domain. Alternatively, an E1 and/or E2/NS1 subunit antigen from a single isolate that maintains conformational epitopes can be combined with a polypeptide composition according to the present invention (e.g., a mixture of synthetic polypeptides or denatured recombinant polypeptides). In another preferred application for vaccines, the polypeptide compositions described herein are combined with other HCv subunit antigens .A .

w0 93/06126 ~'~ ~ ~ PCT/L'S92/0~683 For diagnostic application, it may be useful to employ the compositions of the present invention as antigens, thereby improving the ability to detect antibody to distinct HCV isolates. Typically the polypeptide mixtures can used directly in a homogeneous or heterogeneous immunoassay format, the latter preferably comprising immobilizing the polypeptide on a solid substrate (e. g., microtiter plate wells, plastic beads, nitrocellulose, etc.). See, e.g. PCT Pub. No.
W090/11089: EPO Pub. No. 360,088: IN~itJNOASSAY: A
PRACTICAL GUIDE, supra. Alternatively, each substantially identical polypeptide that makes up the polypeptide composition of the present invention could be immobilized on the same support at discrete loci, thereby providing information as to which isolate or group the antibody has been generated. This may be particularly important in diagnostics if various isolates cause hepatitis, cancer or other diseases wit3i different clinical prognoses. A preferred format is the Chiron RIBA"'' strip immunoassay format, described in commonly owned U.S.S.N. 07/138.894 and U.S.S.N. 07/456,637, the disclosures of which are incorporated herein by reference.
Polypeptides useful in the manufacture of the compositions of the present invention can be made recombinantly, synthetically or in tissue culture.
Recombinant polypeptides comprised of the truncated HCv sequences or full-length HCV proteins can be made up entirely of HCV sequences (one or more epitopes, either contiguous or noncontiguous), or sequences in a fusion protein. In fusion proteins, useful heterologous sequences include sequences that provide for secretion from a recombinant host, enhance the immunological reactivity of the HCV epitope(s), or facilitate the coupling of the polypeptide to a support or a vaccine ._. 9 ~ 1 6 7 8 carrier. See, e.g., EPO Pub. No. 116,201; U.S. Pat. No.
4,722840; EPO Pub. No. 259,149; U.S. Pat. No. 4,629,783.
Full length as well as polypeptides comprised of truncated HCV sequences, and mutants thereof, may be prepared by chemical synthesis. Methods of preparing polypeptides by chemical synthesis are known in the art.
They may also be prepared by recombinant technology. A
DNA sequence encoding HCV-1, as well as DNA sequences of variable regions from other HCV isolates have been described and/or referenced herein. The availability of these sequences permits the construction of polynucleotides encoding immunoreactive regions of HCv polypeptides.
Polynucleotides encoding the desired polypeptide comprised of one or more of the ia~unoreactive 8CV epitope froaa a variable domain of HCv ~y be chemically synthesized or isolated, and inserted into an expression vector. The vectors may or may not contain portions of fusion sequences such as beta-Galactosidase or superoxide dismutase (SOD). Methods and vectors which are useful for the production of PolYPeptides which contain fusion sequences of SOD are described in European Patent Office Publication number 0196056, published October 1, 1986.
The DNA encoding the desired polypeptide, whether in fused or mature form and whether or not containing a signal sequence to pezmit secretion, may be ligated into expression vectors suitable for any convenient host. The hosts are then transformed with the expression vector. Both eukaryotic and prokaryotic host systems are presently used in forming recombinant polypeptides, and a summary of some of the more common control systems and host cell lines is presented infra.
~A .

The host cells are incubated 'under conditions which allow expression of the desired polypeptide. The polypeptide is then isolated from lysed cells or from the culture medium and purified to the extent needed for its intended use.
The general techniques used in extracting the HCV genotne from a virus, preparing and probing DNA
libraries, sequencing clones, constructing expression vectors, transforming cells, performing immunological assays such as radioimmunoassays and ELISA assays, for growing cells in culture, and the like, are known in the art. (See, e.g., the references cited in the "Background"
section, above, as well as the references cited at the beginning of this (~Modes of Practicing the Invention"_ section above.
Transformation of the vector containing the desired sequence into the appropriate host may be by any known method for introducing polynucleotides into a host cell, including, for example, packaging the polynucleotide in a virus and transducing the host cell with the virus, or by direct uptake of the polynucleotide. The transformation procedure used depends upon the host to be transformed. Bacterial transformation by direct uptake generally employs treatment with calcium or rubidium chloride (Cohen (1972), Proc. Natl. Acad. Sci. USA ~$:2110. Yeast transfozination by direct uptake may be carried out using the method of Hinnea et al. (1978), J. Adv. Enzyme Reg.2:1929. Maama~lian transformations by direct uptake may be conducted using the calcium phosphate precipitation method of Graham sad Vas der Eb (1978), Virology x.:546, or the various known modifications thereof. Other methods for the introduction of recombinant polynucleotides into cells, particularly into mammalian cells, which are known in the art include 1~0 93/06126 ij ~ ~ C~ PCT/1592/0~683 dextran mediated transfection, calcium phosphate mediated transfection, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the polynucleotides into :nuclei.
In order to obtain expression of desired coding sequences, host cells are transformed with polynucleotides (which may be expression vectors), which are comprised of control sequences operably linked to the desired coding sequences. The control sequences are compatible with the designated host. Among prokaryotic hosts, ~. ,coli is most frequently used. Expression control sequences for prokaryotes include promoters, optionally containing operator portions, and ribosome binding sites. Transfer vectors compatible with prokaryotic hosts are commonly derived from, for example, pBR322, a plasmid containing operons conferring ampicillin and tetracycline resistance, sad the various pUC vectors, which also contain sequences conferring antibiotic resistance markers. Promoter sequences may be naturally occurring, for example, the i3-lactamase (peaicillinase)(Weissman (1981), "The cloning of interferon and other mistakes" in Interferon 3 (ed. I.
Greaser), lactose (lac)(Chang et al. (1977), Nature x,:1056) and tryptophan (trp)(Goeddel et al. (1980), Nucl. Acids Res. 8:4057), and lambda-derived PL promoter system and N gene ribosome binding site (Shimatake et al.
(1981), Nature x:128). In addition, synthetic pro~notere which do not occur in nature also function as bacterial promoters. For example, transcription activation sequences of one pro~aoter may be joined with the operon sequences of another pra~aoter, creating a synthetic hybrid proanoter (e. g., the tac promoter, which is derived frcan sequences o:f the ~ and ~ promoters (De Hoer et al. (1983), Proc. Natl. Acad. Sci. USA

PC'T/ C. S92/0'683 ~Q:21). The foregoing systems are particularly compatible with E. coli; if desired, other prokaryotic hosts such as strains of Bacillus or Pseudomonas may be used, with corresponding control sequences.
Eukaryotic hosts include yeast and mammalian cells in culture systems. SaccharomvcAg v~ ~a and Saccharomvces rarlsbercenais are the moat commonly used yeast hosts, and are convenient fungal hosts. Yeast compatible vectors generally carry markers which permit selection of successful transformants by conferring prototropy to auxotrophic mutants or resistance to heavy metals on wild-type strains. Yeast compatible vectors may employ the 2 micron origin of replication (broach et al. (1993), Meth. Enz. x:307), the combination of CEN3 and,ARSl or other means for assuring replication, such as sequences which will result in incorporation of an appropriate fragment into the host cell ganome. Control sequences for yeast vectors are known in the art and include promoters for the synthesis of glycolytic enzymes (Hess et al. (1968), J. Adv. Enzyme Reg. 1:149); for example, alcohol dehydrogenase (ADH)(E.P.O. Publication No. 284044), enolase, glucokinase, glucose-6-phosphate isomerase, glyceraldehyde-3-phosphate dehydrogenase (GAP
or GAPDH), hexokinase, phosphofructokinase, 3-glycerophosphate mutase, and pyruvate kinase (PyR)(E.P.O.
Publication No. 329203). The yeast PH05 gene, encoding acid phosphatase, also provides useful promoter sequences. In addition, synthetic promoters which do not occur in nature also function as yeast promoters. For example, upstream activating sequences (UAS) of one yeast promoter may be joined with the transcription activation region of another yeast promoter, creating a synthetic hybrid promoter. B~caa~ples of such hybrid promoters include the ADH regulatory sequence linked to the GAP
transcription activation region (U. S. Patent Nos.

WO 93/06126 2116 7 6 4 P~/~~592/0'683 4,876,197 and 4,880,734). Other examples of hybrid promoters include promoters which consist of the regulatory sequences of either the ADH2, GAL4, GAL10, or PH05 genes, combined with the transcriptional activation region of a glycolytic enzyme gene such as GAP or PyK
(E.P.O. Publication No. 164556). F~rthezmore, a yeast promoter'can include naturally occurring promoters of non-yeast origin that have the ability to bind yeast RNA
polymerase for the appropriate initiation of transcription.
Other control elements which may be included in the yeast expression vector are terminators (e. g., from GAPDH, and from the enolase gene (Holland (1981), J.
Biol. Chem. ,'x:1385), and leader sequences. The leader sequence fragment typically encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. DNA encoding suitable signal sequences can be derived fraaa genes for secreted yeast proteins, such as the yeast invertase gene (E.P.O. Publication No. 12,87:3) and the a-factor gene (U.S. Patent No. 4,588,684). Alternatively, leaders of non-yeast origin, such as an interferon leader, also provide for secretion in yeast (E.P.O. Publication No.
60057). A preferred class of secretion leaders are those that employ a fragment of the yeast a-factor gene, which contains both a ~pre~ signal sequence, and a ~pro°
region. The types of a-factor fragments that can be employed include the full-length pre-pro a-factor leader, as well ae truncated a-factor leaders (U. S. Patent Nos.
4,546,083 and 4,870,008; E.P.O. Publication No. 324274.
Additional leaders employing an a-factor leader fragment that provides for secretion include hybrid a-factor leaders made with a pre-sequence of a first yeast, but a pro- region fraan a second yeast a-factor. (See, e.g., P.C.T. WO 89/02463).

WO 93/061 Z6 s ~ ~ 4 PCT/1.~S92/0'683 _~~4_ Expression vectors, either extrachromosomai replicons or integrating vectors, have been developed for transformation into many yeasts. For example, expression vectors have been developed :Eor Candida ~ (Rurtz et al. (1986), Mol. Cell Hio:l.~:142), ~,y~ maltosa (Runze et al. (1985) J. Basic Microbiol. x:141), Hanzenul~ (Gleeson et al. (1986), J. Gen.
Microbiol. x:3459), Rluyveromvces fra ilis (Das et al.
(1984), J. Hacteriol. x:1165), R ~yverom~r pa lactic (De Louvencourt et al. (1983), J. Hacteriol. ~g:737), pichia guillerimondii, (Runze et al.. (1985), supra), Pichia pastoris (Cregg et al. (1985;x, Mol. Cell. Biol. x:3376;
U.S. Patent Nos. 4,837,148 and 4,929,555)), Schizosaccharomvces pombe (Reach and Nurse (1981), Nature x:706), and Yarrowia liyiolytica (Davidow et al. (1985), Curr. Genet. ~Q:39).
Maamlalian cell lines available as hosts for expression are known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC), including, for example, HeLa cells, Chinese hamster ovary (CHO) cells, baby hamster kidney (BHR) cells, COS monkey cells, and a number of other cell lines. Suitable promoters for mammalian cells are also known in the art and include viral promoters such as that from Simian Virus 40 (SV40), Rous sarcoma virus (RSV), adenovirus (ADV) and bovine papilloma virus (HPV) (See, Sambrook (1989) for examples of suitable promoters). Maaanalian cells may also require terminator sequences and poly A addition sequences; enhancer sequences which increase expression may also be included, and sequences which cause amplification of the gene may also be desirable. These sequences are known in the art.
Vectors suitable far replication in mammalian cells are known in the art, and may include viral replicons, or sequences which ensure integration of the ' ~ ~ WO 93/06126 - ~ 6''~ 6 ~ PCT/L:S92/07683 appropriate sequences encoding the desired polypeptides into the host genome.
A vector which is used to express foreign DNA
and which may be used in vaccine preparation is Vaccinia virus. In this case, the heterologous DNA is inserted into the Vaccinia genome. Techniques for the insertion of foreign DNA into the vaccinia virus genome are known in the art, and utilize, for example, homologous recombination. The insertion of the heterologous DNA is generally into a gene which is non-essential in nature, for example, the thymidiae kinase gene (~), which also provides a selectable marker. Plasmid vectors that greatly facilitate the construction of recombinant viruses have been described (see, for example, Mackett et al. (1984) in "DNA Cloning", Vol. II. IRL Press, p.191, Chakrabarti et al. (1985), Mol. Cell Hiol. x:3403; Moss (1987) in "Gene Transfer Vectors for Maa~nalian Cells"
(Miller and Calos, eds., p. :10). Expression of the desired polypeptides comprised of ia~nunoreactive regions then occurs in cells or individuals which are infected and/or immunized with the live recombinant vaccinia virus.
Other systems for expression of polypeptides include insect cells and vectors suitable for use in these cells. These systems are known in the art,, and include, for example, insect expression transfer vectors derived from the baculovinis a californica nuclear polyhedrosis vines (AcNPV), which is a helper-independeat, viral expression vector. Expression vectors derived fray this system usually use the strong viral polyhedron geae promoter to drive expression of heterologous geaes. Currently the most co~oaly used transfer vector for introducing foreiga genes into AcNPV
is~pAc373. Many other vectors, known to those of skill in the art, have also been designed for improved w0 93/06126 ~ ~ ~ ~ ~ pCTi~~S92/07683 _3h_ expression. These include, for example, pVL985 (which alters the polyhedron start codon from ATG to ATT, and which introduces a HamHI cloning site 32 basepairs downstream from the ATT; See Luckow and Summers (1989), Virology X7:31. Good expression of nonfused foreign proteins usually requires foreign genes that ideally have a short~leader sequence containing suitable translation initiation signals preceding an ATG start signal. The plasmid also contains the polyhedron polyadenylation signal and the ampicillin-resistance (~) gene and origin of replication for selection and propagation in ~.
coli.
Methods for the introduction of heterologous DNA into the desired site in the baculovirus are known in the art. (See Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555; Ju et al. (1987>, in "Gene Transfer Vectors for Mammalian Cells (Miller and Calos, eds.); Smith et al. (1983), Mol. & Cell. Hiol.
x:2156; and Luckow and Summers (1989), supra). For example, the insertion can be into a gene such as the polyhedron gene, by homologous recombination; insertion can also be into a restriction enzyme site engineered into the desired baculovirus gene. The inserted sequences may be those which encode all or varying segments of the desired HCV polypeptides including at least one epitope from a variable domain.
The signals for posttranslational modifications, such as signal peptide cleavage, proteolytic cleavage, and phosphorylation, appear to be recognized by insect cells. The signals required for secretion and nuclear accumulation also appear.to be conserved between the invertebrate and vertebrate cells.
Fxaa~ples of the signal sequences from vertebrate cells which are effective in invertebrate cells are known in the art, for example, the human interleukin 2 signal WO 93/06126 ~ ~ ~ ~ ~ PC1'/~~592/07683 (IL2,) which is a signal for transport out if the cell, is recognized and properly removed in insect cells.
It is often desirable that the polypeptides prepared using the above host cells and vectors be fusion polypeptides. As with non-fusion polypeptides, fusion polypeptides may remain intracellular after expression.
Alternatively, fusion proteins can also be secreted from the cell into the growth medium if they are comprised of a leader sequence fragment. Preferably, there are processing sites between the leader fragment and the remainder of the foreign gene that can be cleaved either ~g vivo or ~ vitro.
In cases where the composition is to be used for treatment of HCV, it is desirable that the composition be immunogenic. In instances wherein the synthesized polypeptide is correctly configured so as to provide the correct epitope, but ie too small to be immunogenic, the polypeptide may be linked to a suitable carrier. A number of techniques for obtaining such linkage are known in the art, including the fo=n~ation of disulfide linkages using N-succinimidyl-3-(2-pyridyl-thio)propionate (SPDP) and succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC> (if the peptide lacks a sulfhydryl group, this can be provided by addition of a cysteiae residue.) These reagents create a disulfide linkage between themselves and peptide cysteine resides on one protein and an amide linkage through the E-amino oa a lysine, or other free amino group in other amino acids. A variety of such disulfide/amide-forming agents are knows. See, for example, Iaaaia. Rev. (1982) ,x:185. Other bifuactioaal coupling agents for a thioether rather than a disulfide linkage. Many of these thio-ether-forming agents are co~nercially available and include reactive esters of 6-maleimidocaproic acid. 2-bromoacetic acid, 2-iodoacetic acid, 4-(N-maleimido-WO 93/06126 PCT/1.~592/076g3 - ~~~s7s~
methyl)cyclohexane-1-carboxylic acid, and the like. The carboxyl groups can be activated by combining them with succinimide or 1-hydroxyl-2-nitro-4-sulfonic acid, sodium salt. Additional methods of coupling antigens employ the rotavirus/~binding peptide~ system described in EPO
Publication No. 259,149. The foregoing list is not meant to be exhaustive, and modifications of the named compounds can clearly be used.
Any carrier may be used which does not itself induce the production of antibodies harmful to the host.
Suitable carriers are typically large, slowly metabolized macromolecules such as proteins; polysaccharides such as latex functionalized sepharose, agarose, cellulose, cellulose beads and the like; polymeric amino acids, such as poiyglutamic acid, polylysine, and the like; amino acid copolymers; and inactive virus particles (see infra.). Especially useful protein substrates are serum albumins, keyhole limpet hemccyanin, immunoglobulin molecules, thyroglobulin, ovalbumin, tetanus toxoid, and other proteins well known to those of skill in the art.
The immunogenicity of the epitopes of the HCV
variable domains, particularly of E1 and E2/NS1, may also be enhanced by preparing them in eukaryotic systems fused with or assembled with particle-forming proteins such as, for example, that associated with hepatitis H surface antigen. See, e.g., U.S. Patent No. 4,722,840.
Constructs wherein the polypeptide containing the HCv epitope from a variable domain is linked directly~to the particle-forming protein coding sequences produces hybrids which are iamminogenic with respect to the HCV
epitope. In addition, all of the vectors prepared include epitopes specific to HHV, having various degrees of immunogenicity, such as, for example, the pre-S
peptide. Thus, particles constructed from particle WO93/06126 2116' f 4 P~/L592/0'683 _3G_ fozzning protein which include HCV sequences are immunogenic with respect to HCV and HHV.
Hepatitis surface antigen (HHSAg) has been shown to be formed and assembled into particles in ~.
cerevisiae (Valenzuela et al. (1982), Nature x:344, as well as in, for example, mammalian cells (Valenzuela et al. (1984), in "Hepatitis H", Millman I. et al., ed.).
The formation of such particles has been shown to enhance the immunogenicity of the monomer subunit. The constructs may also include the immunodominant epitope of HHSAg, comprising the 55 amino acids of the presurface (pre-S) region. Neurath et al. (1984). Constructs of the pre-S-HHSAg particle expressible in yeast are disclosed in E.P.O. Publication No. 174,444; hybrids including heterologous viral sequences for yeast expression are disclosed in E.P.O. Publication No.
175,261. These constructs may also be expressed in maa~alian cells such as C80 cells using an SV40-dihydrofolate reductaae vector (Michelle et al. (1984)).
In addition, portions of the particle-forming protein coding sequence may be replaced with codons encoding an epitope from an HCV variable domain. In this replacement, regions which are not required to mediate the aggregation of the units to form immunogenic particles is yeast or maaanals can be deleted, thus eliminating additional HHV antigenic sites from competition with the HCV epitope(s).
The preparation of vaccines which contain an immunogenic polypeptide(e) ae as active ingredients) is known to one skilled in the art. Typically, such vaccines are prepared ae injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or ~uspenefoa in" liquid prior to injection may also be prepared. the preparation may also be emulsified, or the polypeptide(s) encapsulated in WO 93/06126 ~ ~ ~ ~ ~ p['f/L'S92/076g3 liposomes. The active immunogenic ingredients are often mixed with excipients which are phazznaceutically acceptable and compatible with the active ingredient.
Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof. In addition, if desired, the vaccine may contain.minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine. Examples of adjuvants which may be effective include, but are not limited to: aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637), referred to as nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (CGP 19835A, referred to as MTP-PE, and RIHI, which contains three components extracted fro~a bacteria, monophosphozyl lipid A, trehalose dimycolate and cell wall skeleton (MPL+TDM+CwS) in a 2~ squalene/Tween 80 emulsion. The effectiveness of an adjuvant may be determined by measuring the amount of antibodies directed against an immunogenic polypeptide containing an HCV epitope from a variable domain, the antibodies resulting from administration of this polypeptide in vaccines which are also comprised of the various adjuvaats.
The proteins may be forntulated into the vaccine as neutral or salt forn~s. Pharmaceutically acceptable salts include the acid addition salts (formed with free amino groups of the peptide) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or organic acids such as acetic, oxalic, tartaric, aisleic, and the like. Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, . , WO 93/06126 21 ~ ~ ,~ 6 ~ P~/l'S92/07683 - 41 ~~
ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.
The vaccines are conventionally administered parenterally, by injection, for example, either subcutaneously or intramuscularly. Additional forntulations which are suitable for other modes of administration include suppositories and, in some cases, oral formulations. For suppositories, traditional binders and carriers may include, for example, polyalkylene glycols or triglycerides;such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5~ to 10~, preferably 1~-2~.
Oral formulations include such nornnally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like.
These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10~-95~ of active ingredient, preferably 25t-70~.
In addition to the above, it is also possible to prepare live vaccines of attenuated microorganisms which express recombinant polypeptides of the FiCV antigen sets. Suitable attenuated microorganisms are known in the art and include, for example, vinises (e. g., vaccinia virus) as well as bacteria.
The vaccines are administered is a manner coanpatible with the dosage formulation, and in such amount as will be prophylactically and/or therapeutically effective. The quantity to be admiaistered, which is generally in the range of 5 ~g to 250 ~g of antigen per dose, depeads on the subject to be treated, capacity of the subject s iamune system to synthesize antibodies, and the degree of protection desired. Precise amounts of WO 93/06126 2116' ~ 4 PC'T/1~S92/0~683 active ingredient required to be administered may depend on the judgment of the practitioner and may be peculiar to each individual.
The vaccine may be given in a single dose schedule, or preferably in a multiple dose schedule. A
multiple dose schedule is one in which a primary course of vaccination may be with 1-10 separate doses, followed by other doses given at subsequent time intervals required to maintain and/or reenforce the immune response, for example, at 1-4 months for a second dose, and if needed, a subsequent doses) after several months.
The dosage regimen will also, at lest in part, be determined by the need of the individual and be dependent upon the judgment of the pzactitioner.
In addition, the vaccine containing the antigen seta comprised of HCV polypeptides described above, may be administered in conjunction with other immunoregulatory agents, for txample, immune globulins.
The compositions of the present invention can be administered to individuals to generate polyclonal antibodies (purified or isolated from serum using conventional techniques) which can then be used in a number of applications. For example, the polyclonal antibodies can be used to passively immunize an individual, or ae immunochemical reagents.
In another embodiment of the invention, the above-described immunoreactive compositions comprised of a plurality of >3CV antigen sets are used to detect anti-8CV antibodies within biological samples, including for example, blood or serum samples. Design of the immunoassays is subject to a great deal of variation, and a variety of these are known in the art. However, the inmunoassay will use antigen sets wherein each antigen set consist, of a plurality of subataatially identical polypeptidee comp=ieing the amino acid sequence of an w0 93/06126 ~ ~ ~ I~ PCT/ (. S92/07683 epitope within a first variable domain of an HCV isolate, and the amino acid sequence of one set is heterogeneous with respect to the amino acid sequence of at least one other set. Protocols for the immunoassay may be based, for example, upon competition, or direct reaction, or sandwich type assays. Protocols may also, for example, use solid supports, or may be by immunoprecipitation.
Most assays involve the use of labeled antibody or polypeptide; the labels may be, for example, fluorescent, chemiluminescent, radioactive,. or dye molecules. Assays which amplify the signals from the probe are also known;
examples of which are assays which utilize biotin and avidin, and enzyme-labeled and mediated immunoassays, such as ELISA assays.
Rits suitable for immunodiagnosis and contain-ing the appropriate labeled reagents are constructed by packaging the appropriate materials, including the compositions of the invention containing HCV epitopes from variable domains, in suitable containers, along with the remaining reagents and materials (for example, suitable buffers, salt solutians, etc) required for the conduct of the assay, as well as a suitable set of assay instructions.
Described below are examples of the present invention which are provided anly for illustrative purposes, and not to limit the scope of the present invention. In light of the present disclosure, numerous embodimeats within the scope of the claims will be appar-ent to those of ordinary skill is the art.

WO 93/06126 2116'7 6 4 P~/~~592/0?683 In the Examples the following materials and methods were used.
Pati ent Satt~les and RNA Extra r; r", Asymptomatic HCV carriers HCT 18 and HCV J1 and chronically infected HCV patient Th have been previously described in Weiner et al. (1991) Virol. 180:842-848.
Patient Q was diagnosed with chronic active hepatitis based on a liver biopsy and was placed on alfa-2b interferon therapy (3 million units, thrice weekly) for six months. RNA from 0.2 ml of plasma was extracted according to the method of Chomcynski and Sacchi, (1987) Anal. Biochem. x,:156-159, using RNAzolT''' H reagent (Cinna/Biotecx Laboratories) containing 10 ~g/ml MS2 carrier RNA (Hoehringer Mannheim, 165-948) as indicated by the manufacturer. RNA was resuspended in 200 ~1 of diethyl pyrocarbonate treated distilled water and reprecipitated in a final concentration of 0.2M sodium acetate and two and one half volumes of 100 ethanol (-20°C) .
cDNA and Pollrmerase Chain Reactions All reactions were performed according to Weiner et al. (1990) Lancet ~:1-5. M13 sequencing was performed according to Messing et al. (1983), Methods in Enzymology x:20-37. The consensus sequence of at least four cloned inserts are presented with the exception of the HCV J1.2 E2/NS1 sequence which was derived from two closes.
Cloning and sequencing of HCT 18 and Th was as reported in Weiner et al. (1991), supra. Nested PCR
primers used to clone the amino tezminal and carboxy proximal segments of E2/NS1 in patient Q were:
PCR I
X(E2)14 GGTGCTCACTGGVGAGTCCT(1367-1386)S

H'O 93/06126 ~ ~ ~ ~ t~ PCT/yS92/0?683 X(E2)18J CATTGCAGTTCAGGGCCGTGCTA(1608-1588)A, PCR II
X(E2)4 TCCATGGTGGGGAAC1'GGGC(1406-1425)S
X(E2)19J TGCCAACTGCGATTGGTGTT(1582-1562)A;
PCR I
X ( E2 ) 14 ( above ) S
Jlrcl2 TAACGGGCTGAGCTCGGA(2313-2296)A
PCR II
US(E2)5 CAATTGGTTCGGTTGTACC(1960-1978)S
Jlrcl3 CGTCCAGTTGCAGGCAGCT'I~C(2260-2240)A.
PCR primers used to clone the IiCV J1 E2/NS1 gene were:
PCR I
J1(E2)14 (above)S
J1(E2)rc30" CACCGCAGTATCTGCCACTC(2349-2330)A
J1IZ-2' TGAGACGGACGTGCTGCTCCT(1960-1978)S
J1(E2)rc32'~ TTTGATGTACCAGGCGGCGCA(2658-2636)A
PCR II-~2384.5 GGATCCGCTAGCCATACCCGCGTGACG~C~C~GGGGGTGCAA(1469-1495)S
DSCON1JHX~
GGATCCTCTAGATTACTCTTCTGACCTATCCCTGTCCTCCAAGTC
ACA(2272-2301)A
J1IZ-1~ CAACTGGTTCGGCTGTACA(1915-1935)S
J1(E2)rc31" (2566-2546)A.
', nt sequence from Takeuchi et al., (1990) Nucl. Acids Res. ~g:4626; ", nt sequence from Rato et al., (1989) Proc. Jpn. Acad. x$:219-223. Sense (S) or antisense (A) PCR primers are given in the 5' to 3' orientation according nucleotide numbers in reference.
Synthesis of Hiotiaylated P~~
The overlapping octapeptides for the hypezvariable regions of three strains of HCV were synthesized on cleavable-linker, derivatized, polyethylene pine essentially as described by (Maeji et al., (1990) J. Immunol. Methods x:23-33, was coupled to the N-terminus of each peptide. Finally, biotin was coupled to the N-terminus using 150 ~1 of a dimethylfozmamide solution containing 40 mM biotin, 40 mM
1-hydroxybenzotriazole (HOHt), 40 mM
benzotri~azole-1-yl-oxy-tris-pyrrlidino-phosphonium hexafluorophosphate (PyHOP* NOVAHIOCHEM) and 60 mM
N-methylmorpholine (NMM) reacting overnight at 20'C.
After biotinylation, the peptides were side-chain deprotected, washed and. the peptide from each pin was cleaved in 200 ~1 of O.iM phosphate buffer (pH
7.2). Microtitre plates containing the cleaved peptide solutions were stored at -20'C until needed.
ELISA Testinc of Hiot~nviaror~ pefltid g Polystyrene plates (Nunc immuno plate maxisorb F96) were coated with streptavidin by incubating overnight at 4°C with 0.1 ml/well of a 5 ~g/ml solution of streptavidin (Sigma Cat. Na. S4762) in 0.1 M carbonate buffer at pH 9.6. After removal of the streptavidin solution, the wells were washed four times with a 0.1~
solution of Tween 20*in PHS. Nonspecific binding was blocked by incubating each well with 0.2 ml of 2~ HSA in PHS for 1 h at 20°C. The wells were again washed four times with PHS/Tween 20r Plates were air-dried and stored at 4°C until required. The streptavidin in each well was coupled to cleaved peptides by incubation with 100 ~l of a 1:100 dilution of cleaved peptide solution with 0.1~ BSA in PHS containing 0.1~ sodium azide for 1 h at 20°C. After incubation, the plate was washed four times with PHS/Tween 2f1~ 8ach well was incubated with 100 ~1 of a suitable dilution of sezvm (diluted with 2t HSA in PHS containing O.it sodium azide) for 1 h at 20°C
or overnight at 4°C followed by four washes with * tradanark i'A

. 4~- 2 1 1 6 7 6 4 PHS/Tween 20* Hound antibody was detected by reaction for 1 h at 20°C in 0.1 ml conaugate. This consisted of 0.25 ml/1 (a saturating level) of horseradish peroxidase-labeled goat anti-rabbit IgG (H+L) (Kirkegaard and Perry Labs, Gaithersburg, MD) in CASS (O. it sheep senun, 0.1~
. Tween 20k, 0.1~ sodium caseinate diluted in 0.1M PHS, pH
7.2). The wells were washed 2 times with PHS/Tween 20*
followed by two washes with PHS only. The presence of enzyme was detected by reactian for 45 min at 20'C with O.iml of a freshly-prepared salution containing 50 mg of ammonium 2,2'-azino-bis[3-ethylbenzothiazoline-6-sulphonate (ARTS, Hoehringer Mannheim Cat. no. 122661) and 0.03 ml of 35~ (w/w) hydrogen peroxide solution in 100 ml of 0.1 M phosphate/0.08 M citrate buffer, pH 4Ø
Color development was measured in a Titertek*Multiscan MC
plate reader in the dual wavelength mode at 405 nm against a reference wavelength of 492 nm.
~OmDLteZ' GeneratA~ nntiQAnirity prpfilB
Antigenicity profiles for the HCV E2/NS1 protein and HIV-1 gp120 hypezvariable region V3 (aa 303-338) were derived from a computer program based on the degree of sequence variability as originally proposed by Rabat [Sequences of proteins of immunological interest.
U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health (1983)] for the identification of the hypervariable loops of immunoglobulins multiplied by the average of the individual probability that antibody binding is retained for each possible pair-wise amino acid. Probabilities for retention of antibody binding associated with a given amino acid change were the values experimentally determined by assessing the effects on antibody binding of all possible amino acid substitutions for 103 characterized linear epitopes. Geysen et al., (1988) J.
* trademark iA

WO 93/06126 2 1 1 6 7 6 4 P~/(.S92/07683 Mol. Rec. x:32-41. This algorithm thus weights the variability index to give more significance to amino acid changes likely to have a significant effect on antibody binding, i.e., compensates fo:r conservative amino acid changes. Fifteen HCV sequences [HCV-1, Q3.2, HCT 23, EC10, HC-J1, HCVEl, TH, HCT 2"7, Q1.2, HCT18, HC-J4, HCV
J1.2/HCV Ji.i, HCV J , HCV HR:~, were used to determine the antigenicity profile for HCV. The HIV-1 V3 profile was obtained by averaging 242 individual profiles of 15 sequences selected at random from the numerically greater data base of unique HIV-1 sequences. LaRosa et al., (1990) Science ~,g,Q:932-935 & Correction in Science (1991) p. 811. The amino acid sequences of some of these isolates between as 384 and 420 are shown in Figure 3.
The a-helix, ~-sheet and ~-turn secondary st picture probabilities for the amino-terminal region (384-420) were determined using an algorithm, which assigns the probabilities for each of the three above secondary structural motifs to each residue. The coefficients used in the algorithm were obtained for all pair-wise combinations of residues of the structural data base. Levitt and Greer, (1977) J. Mol. Hiol.
~,g,:181-293. The prediction parameters obtained from these coefficients were fitted to the observed outcome when the algorithm was applied back on the database to obtain probabilities that a given residue would be found in one of the three defined secondary structural motifs.

WO 93/06126 ~ 116 7 6 4 P~/~~S92/0'683 Example 1 Comparison of Secondary Structure and Amino Acid Sequence Variation in the HCV E2/NS1 HV
and HIV-1 a~120 Domains The amino acid sequences from fifteen HCV and HIV-1 isolates were compared with respect to the number of positions at which amino acid sequence heterogeneities were observed in the HCV E2 HV or HIV-1 gp120 V3 domains (Figure 4, A and H, respectively). Amino acid heterogeneities occurred in 25 of 30 amino acid positions in the E2 HV region and 23 of 35 amino acid positions in the HIV-1 gp120 V3 domain. Dashes on the x-axis of Figure 4 A and H represent amino acid positions where variable amino acid residues occur and invariant amino acids are given in the single letter amino acid code.
The antigenicity profiles shown in Figure 4 indicate that, similar to the V3 loop of the HIV-1 gp120 protein (Figure 4H), a block of amino acid residues in the HCV E2 (amino acids 384-414 in Figure 4A) was identified whose !,variation had a predicted adverse affect on antibody !binding. The data in figure 4 indicate that the HCV E2 domain resembles the HIV-1 gp120 V3 domain, which is known to encode virus neutralizing epitopes, in both the degree and predicted significance of observed amino acid variation and suggests that the E2 HV domain may have a similar function as the gp120 V3 domain.
Linear epitopes are more likely associated with less structured regions of proteins, in particular, the ends of proteins or with exteaded surface loops. A
computer analysis was used to predict the probability that as individual residue is associated with a defined secondary structural motif for 15 E2 HV amino acid sequences between residues 384 to 420. Figure 4 shows WO 93/06126 2 1 1 6 7 6 4 PCT/L~S92/076g3 that the region between the E2 amino-terminal residue 384 and the strongly predicted, highly conserved beta-turn (residues 415-418) is relatively unstructured as indicated by less than 50 percent probability of alpha-helix, beta-sheet or beta-turn character. Lack of strongly predictive structure in the E2 HV domain is consistent with the tolerance for extensive sequence variation found between isolates and is in contrast with highly structured regions which contribute to tertiary folding of the protein. The HCV E2 HV domain appears to be even less structured than the V3, principal neutralizing domain of HIV-1 gp120, which has been reported to contain a beta strand-type II beta turn-beta strand-alpha helix motif and may have greater structural constraints on amino acid variability than the HCV E2 HV
domain. Taken together, the evidence suggests that the E2 HV domain appears to have features characteristic of protein domains which contain likely sites of linear neutralizing epitopes.
Overlapping biotinylated 8-mer peptides corresponding to and extending past the E2/NS1 HV domain (wino acids 384 to 416) of HCT 18 (A,D), Th (H,E) and HCV J1 (C, F) were bound to plates coated with streptavidin and reacted with plasma from either HCT 18 (A-C) or Th (D-F). The results are shows in Figure 6 for HCV isolates HCT 18 (Fig. 6A and 6D), Th (Fig. 6H and 6E), and HCV J1 (Fig. 6C and 6F). HCT 18 plasma was diluted 1:200 and Th plasma was diluted 1:500. HvE-1, -2, -3, -4 and -5, represent isolate specific epitopes.
As seen from Figure 6, HCT 18 plasma identi-fied a linear epitope ('°'PKQNV"") .when tested with -51- 21 16 7 6 ~4 peptides derived from the HCT18 sequence (HVE-I in Figure 6A), but failed to react with peptides corresponding to the HV
domain of two different strains Th and HCV J1 ( Figures 6B
and 6C). In contrast, Th plasma identified linear epitope HVE-IV in the HV domain. of Th (9°9QNIQLI914, Figure 6B, panel E) , and also epitopes in strain HCT 18 (39qIVRFFAP9°5, Figure 6A,panel D), and HCV J1. Th, an IV drug user, may have been exposed to multiple strains of HCV.
Hoth Th and HCT 18 plasma each reacted with an epitope (amino acids 413-419) common to all three isolates (data not shown) when used in an ELISA with pin synthesized overlapping 8mer peptides from each isolate.
In. order to validate antibody binding specificity, antibodies bound to biotinylated peptides containing amino acids 403-40'7 were eluated and used to block the reactivity of HCT 18 plasma with pins containing overlapping 8-mere for the HCT 18 HV domain.
These data indicate that 1) the E2/N51 HV domain is immunogenic, 2) there are multiple epitopes which map to this region, and 3) a subset of epitopes (HVE-1, -2, -3, -4 or -5 in Figure 6) in the HV domain are isolate specific.
ale 3 Determination that yariant E2/NS1 HV Domains ~a_n_ He Associated With Flares of Hepatitis To investigate the possibility of finding HCV
variants associated with the iatennittent flares of hepatitis often found in chronic HCV infections, we artiall se enced the E2/NS1 P y Qu gene from a patient, Q, with chronic hepatitis during two distinct episodes of hepatitis approximately two years apart (Q1 and Q3, respectively). The second episode of hepatitis occurred 1.5 years after the termination of interferon treatment.
~A

W'O 93/06126 ~ ~ ~ ~ ~ PC~'/1S92/076g3 _52_ The differences in the deduced amino acid sequence of the Q1 and Q3 E2/NS1 HV region was strikingly different only between amino acids 391-408 with seven of eight changes occurring between amino acid 398 and 407 (Figure 7). Figure 7 shows the deduced amino acid sequences of two regions of the E2/NS1 polypeptide, amino acids 384-414 and 547-647, for the Q1 and Q3 isolates.
The amino acid (E) above the Q1 sequence was found in one of four Q1 clones. The boxed amino acids represent the location of the Q1 or Q3 HVE l2mer peptide. Amino acid sequence differences found between Q1 and Q3 are printed in bold type.
Only one amino acid heterogeneity was observed between amino acids 547 and 647 of the Q1 and Q3 E2/NS1 polypeptides (Figure 7).
To examine the effect of the amino acid substitutions observed in the Q1 and Q3 E2 HV domains on aatibody binding, we synthesized a Q1 and Q3 specific 12-mer peptide from amino acids 396 to 407 (HVE Q1 or Q3 in Figure 7H) and separately reacted the Q1 and Q3 plasma with each peptide in an ELISA. Table 4 shows that antibodies in both the Q1 and Q3 plasma reacted with the Q1 peptide but not with the Q3 peptide. Statistical analysis (Student's Test) indicated that the binding of the Q1/Q3 plasma to the Q1 peptide was significantly above background binding of those plasma to a panel of 12 raadomly chosen control peptides (P<0.001), while binding of either the Q1 or Q3 plasma to the Q3 peptide was not statistically significant. The data indicate that although patient Q developed antibodies to the HCV Q1 Hv domain, which were still detectable two years later at the Q3 time point, no detectable humoral response had developed to the Q3 E2 HV variant which was predominant during the second episode of hepatitis.

-53- 2 1 16 7 6 4~
Table 4 $lisa Results on12-mer Peptides TARFAGFFQSGA TAGFVRLFETGP
Plasma Q1 seq Q3 seq Mean sd Mean sd Q1 1.158 0.134 0.691 0.123 Q3 1.022 0.123 0.93 0.036 E~,1~4 Detection of Coexis~ina E2/NS1 Genes With Distinct E2/NS1 HV Domains in HCV Infected Individuals Figure 8A shows the amino acid sequences deduced from two isolates of HCV J1 (J1.1 ~ J1.2> which were cloned fzom one plasma sample of the Japanese volunteer blood donor HCV J1_ Kubo et al., (1989) Nucl.
Acids Res. X7:10367-10372. bf the 23 total amino acid changes between HCV J1.1 and HCV J1.2, 9 differences indicated by bold type are clustered in the 30 amino acid E2/NS1 HV domain. Five of the 9 amino acid substitutions in the E2/NS1 HV domain represent nonconservative amino acid changes. Since HCV J1 is the only group II HCV
genome which has been cloned in our laboratory, it is unlikely that these differences are due to cross contami-nation of the HCV J1 plasma. The HCV J1.2 sequence represents a minority sequence in HCV Ji~s blood since only two E2/NS1 HV variant sequences were identified from ~ cloned sequences which originated from two independent PCR reactions.
Interestingly, a comparison of the HCT27 and HCV E1 isolates (Figureg_2), which were sequenced in different laboratories and derive from presumably ~related.individuals, showed that the number of amino ~A

acid differencE:s in the E2/NS1 MV domain of these isolates were fewer than the number of differences observed between isolates from the same individual.
The above described results lead to the suggestion that. the HCV genome is rapidly evolving in individuals and the population.
~vTnrtnT ~ c Formulation and Preparation of Vaccine Coupling of thE~ Diphtherip Toxoid Carrier Protein to MCS
Materials Requured ethylene diamine-tetra-acetic acid (EDTA Na2.2H20) (MW
372) 6-inaleimido-caproic acid N-hydroxysuccinjmide ester (MC:S) (Sigma) -95%pure sodium dihydrogen orthophosphate (NaH2P09) nitrogen dimethylfonmam__de (DMF) Milli Q water 0.1 M phosphate buffer containing 5 EDTA, pH 6.66 0.1 M phosphatE~ buffer, pH 8.0 0.1 M phosphate buffer, pH 7.0 sodium succinat:e [ ( CHZCOONa ) 2 . 6H20 ]
cysteine hydrochloric acid (21 solution) 0.1 M sodium succinate/0.1 EDTA, pH 5.6 Purified diphtheria toxoid (Comonwealth Serum Laboratories, Victoria, Australia) was coupled to MCS
according to the method described by Lee et al., (1980) Mol. Ixmnunol. 17:749; Partis et al., (1983) Prot. Chem 2:263; Peeters et al., (1989) J. Immuunol. Methods 120:133; Jones et al., (1989) J. Immunol. Methods 123:211. 100 m:L of diphtheria toxoid was passed through a G25 Sephadex''M column (l7cm X 4 cm) to remove thiomers The toxoid was eluted with 0.1 M phosphate buffer pH 7.0 and the protein content of the eluate was assayed using the ECA protein determination (Pierce ). The resulting H'O 93/06126 2116 7 6 4 p~/~'S92/0~683 solution was concentrated using.an Amicon ultrafiltration unit ~o a final concentration of 10 mg/ml.
One milliliter of the toxoid solution was dialyzed with 0.1 M phosphate buffer, pH A.O, and then mixed with a solution of 1.5 mg MCS in 200 ~1 DMF. The resulting solution was incubated at room temperature for 1 hour is the dark With occasional mixing. In order to separate the uncoupled MCS from the MCS-toxoid, the solution was passed through a Sephadex PD10 column which had been equilibrated with 0.1 M phosphate buffer, pH
6.66 and the protein fraction was collected.
The number of maleimido groups coupled per carrier molecule was determined prior to coupling of the HCV peptides thereto. Thirty milliliters of the succinate/EDTA buffer was sparged with nitrogen for 2 minutes. Five milligrams of cysteine was transferred into a 25 ml volumetric flask and dissolved in a final volume of 25 ml of the sparged buffer. Aliquots of the solutions shown in Table 5 were transferred in duplicate to 25 ml screw capped bottles.. Using separate pipettes, nitrogen was bubbled into each aliquot. Each bottle was then sealed and incubated at room temperature in the dark for 40 minutes with occasional swirling.
Table 5 Solution Saamle (ml) Standard (ml) Blank (ml) activated carrier 0.3 - -pho~phate butter - 0.3 0.3 cysteine solution 1.0 1.0 -succinate buffer - - 1.0 t A 0.1 ml aliquot of each of the 3 solution was taken for an Ellman's determination.

WO 93/06116 2116 7 6 4 P~./~S9Z/07683 E~lman's Test for the Ouantitar;~o pore.",;., n of Sul f hyd~
Materials Required Phosphate buffer, pH 8.0 Dissolve 15.6 g NaH~PO, or 12.0 g NaH=P0, anhydrous in approximately 700 ml Milli Q water. Adjust the pH to 8.0 using 50~ NaOH. Add Milli Q water for a final volume of 1000 ml and then adjust the pH if necessary.
Ellman's Reagent Dissolve 10.0 mg of 5,5'-dithiobis-2-nitrobenzoic acid (DTNH) in 2.5 ml of phosphate buffer, pH 8.0 0.1 ml of Ellman's reagent was added to each of the 0.1 ml aliquots of the solutions prepared above, namely the sample, standard and bland solutions. Five milliliters of phosphate buffer, pH 8.0, was then added to each aliquot, mixed well and allowed to stand for 15 minutes. The absorbance of each aliquot was measured in a 1 cm path length cell at 412 am.
The number of maleimido groups present on the carrier protein was determined according to the following method. A 0.01 ~cmol per ml solution of -SH produces an absorbance of 0.136 in a 1 cm light path at 412 nm. The absorbance of the Standard or Sample (A) is equal to the amount of cysteine reacted with the coupled maleimido groups on the activated carrier protein. Since 1 mol of available -SH reacts with 1 mol of maleimido, the concentration in ~uaols of the maleimido groups present in the aliquot tested is equal to A(0.01)/0.136 ~rmol/ml.
The total volume of the solution was 5.2 ml. Therefore, the total number of ~mols present was equal to A(0.01)(5.2)/0.136. The sample solution had a total volume of 1.3 ml, of which 0.3 ml consisted of the activated carrier protein. The amount of maleimido groups present in the sample solution was calculated as A(0.01) (5.2) (1.3) / (0.136) (0.1) (0.3) ~ A(16.57) ~unol/ml.

. . , ~ 57 The MCS-activated cagier protein was stored at -20°C.
Reduction of tree HCV Peotides Prior to coupling of the HCV peptides to the MCS-activated carrier protein, the peptides were reduced to ensure that thiol groups present on the pept ides were in the fiilly reduced -SH form.
Materials Requ__red dithiothreitol (DTT) ammonium hydroq_ en carbonate (NH4HC01) methanol SEP-PAKsTM(C18 cartridge, Waters), 1 cartridge for each 8 mg of peptide 0.1 M ammonium hydrogen carbonate buffer Dissolve 7. 9 g NH4HC03 in 1 Milli Q
water Buffer A, 0.1% v/v trifluoroacetic acid (TFA) in Milli Q
water Buffer B, 60% v/v acetonitrile, 0.% v/v TFA in Milli Q
water 15 mg' of each of two HCV pept ides corresponding to amino acids 384-411 and 225-260, respectively. of the HCV polyprotein were added to 2.5 ml pf 0.1 M armonium hydrogen carbonate containing a 10 fold molar excess of DTT. The result:ing solutions were mixed until the peptide had dissolved and were then atlowed to stand for 1 hour at room temperature. Two pairs of SEP-PAKs were connected in series and activated by passing approximately 20 ml of methanol and then 20 ml of Buffer. A through each pair of SEP-PAKsTM. Each peptide/DTT sample was slowly passed through a pair of SEP-PAKsTM. The DTT was eluted with 20 ml of Buffer A. The reduced peptide was eluted with 7 ml of Buffer B int:o pre-weighed bottle and then freeze-dried overnight. The bottles were then weighed to determine the amount of recovered peptide. The reduced peptides were then immediate_Ly coupled to the MCS-activated carrier protein.

Coupling HCV Peptides to MCS-Activa p~ CarripT Drnro;., Approximately 100 ml of 0.1 M phosphate buffer with 5-mM EDTA; pH 6.66 was degassed under vacuum and then sparged with nitrogen fox 10 minutes. Twenty milliliters of a l0 mg/ml solution of the MCS-activated carrier protein was carefully sparged with nitrogen to prevent excessive frothing. 5 mg of each of the reduced peptides were dissolved~in approximately 0.2 ml of the degassed aparged phosphate/EDTA buffer, pH 6.66 and then mixed with the MCS.-activated carrier protein solution.
The resulting mixture~was transferred into.a screw capped bottle which was then filled with nitrogen and sealed.
The solution was further degassed by holding the bottle in a Hranson 2000~ sonication bath for 2 minutes. The bottle was covered with aluminum foil and incubated overnight at room temperature-with slow mixing on a shaker table.
The resultant conjugate was soluble and the uncoupled peptide was removed by passing the mixture over a Sephadex PD 10*column which had been equilibrated with the phosphate/EDTA buffer, pH 6.66. The protein fraction was collected. The amount of peptide conjugated to the carrier protein was determined by amino acid analysis.
An amigo acid analysis of 150 ~1 aliquots of both the conjugate and the carrier protein was performed.
The average ratio of the level of amino acids contributed solely by the carrier protein was determined to calculate the amount of conjugated peptide produced: Levels of eerine, threoaiae, tiyptophan, methionine, tyrosine and cysteine were not determined as these amino acids are modified under the standard hydrolysis conditions.
Typical results obtained in these calculations are presented in Table 6.
* tradanark A

21 16764 v Table 6 AMINO ACID CARRIER ONLY CONJUGATE

P 79 li3 For the conjugate, the values in bold type are the amino acids that were also present in the peptides.
For conjugates containing alanine and proline, the factor (193+179+180+56)/(212)+194+153+60) = 0.8659 is multiplied by the amount of the amino acid level in order to normalize the result.
preparation of Vaccine Composition Injectable compositions consisting of HCV
peptides conjugated to MCS-activated diphtheria toxoid carrier protein prepared as described supra and a submicron oil-in-water emulsion adjuvant as described in PCT International Publication No. W09014837, published December 13, 1990. In addition, injectable compositions containing an immunostimulant, lipophilic muramyl peptide (MTP-PE, CIBA-GEIGY, Basel, Switzerland) in addition to HCV conjugated peptides and adjuvant were prepared. The vaccine compositions were generally comprised of 500 protein and 50o adjuvant.
Formula for Vaccine Com~oaitien with MTP-PE
3o To prepare l0 ml of injectable vaccine composition:
2.5 ml Squalene (Sigma Chemical Co., St. Louis, Ho.) 0.25 ml Tween 80*(Sigma Chemical Co.) 0.25 ml SPAN 85*(Sigma Chemical Co.) 1000 ~g lriTP-PE
1'000 ~g IiCV peptide conjugated to MCS-activated diphtheria toxoid carrier protein * trademark Fer,nu7a for Vaccine Composition without MTp pE
To prepare 10 ml. of injectable vaccine composition:
2.5 ml Squalene (Sigma Chemical Co., St. Louis, Mo.) 0.25 ml Tween 80*(Sigma Chemical Co.) 0.25 ml SPAN 85*(Sigma Chemical Co.) 1000 ~g HCV peptide conjugated to MCS-activated diphtheria toxoid carrier protein Example 6 Method for Testiaq Vacs Preaarations for Toxicity Vaccine prepared according to the methodology of Example 5 was tested for toxicity in small animals.
Fifty microgram per kilogram of vaccine was administered to inea gu pigs, mice and rabbits by intraperitoneal injection. The vaccine was also administered by intraperitoneal injection to rhesus monkeys and primates.
Half of the test population o! rhesus monkeys and primates received 5 ~g/kg doses of the vaccine, while the over half received 50 ~g/kg dosages. Control animals employed in each of the studies were injected with a comparable amount of a composition consisting of the components of the vaccine preparation except the viral peptides.
Each of the animals was monitored for symptoms indicative of a response to toxic material. More specifically, each animal in the study was examined bi-weekly for symptoms including fsver, lethargy, weight loss, changes in eating habits and for lesions, swelling or tenderness at the site of injection. Lymph nodes proximal to the injection site were also examined for swelling and/or drainage. The animals were monitored on a bi-weekly basis for a period of several months.
* tradanark ., ' ' ~ WO 93/06126 2 1 1 6 7 6 ~ P~/~ S92/07683 Exa~~le 7 Vaccine prepared according to the methodology of Example 5 was tested in chimpanzees in order to determine the effectiveness o! the vaccine in eliciting the production of virus neutralizing antibody in vaccinated subjects. Chimpanzees were vaccinated with 5 ~g/kg dosages of vaccine prepared according to the methodology of Example 5 oust a six-month time period at intervals of 0, 1, 3 and 6 months. Control chimpanzees were injected with comparable amounts of a composition consisting of the components of the vaccine except the viral peptides. Two weeks after the last dose of vaccine was administered, the test and control chimpanzees were each challenged with a 10 CIUm (Chimpanzee Infectious Unitj doss of CDC/910 plasma inoculum. Commencing one weak following the viral challenge, each o! the chimpanzees was monitored for viremia on a weakly basis.
In order to detect viremia, blood samples and liver biopsy specimens wars collected from control and test animals on a weekly basis for several months.
Tissue collected by liver biopsy was examined histologically for signs of necrosis and/or inflammation.
Zn addition, hepatocytes from the biopsy material were examined by electron microscopy !or the presence of tubules characteristic of HCV infection. The blood samples ware also analyzed by the ELISA assay described supra for the presence of antibodies to segments of viral polypsptides which were not utilized in preparing the vaccine. In particular, each o! the blood samples was screened by ELISl~ !or the presence o! antibodies to NSF, NS,, and NSs peptides. The presence of antibodies to WO 93/06126 2 i i 6 7 s 4 p~~ys92/0~683 -6x-these peptides in the serum of a chimpanzee was indicative of HCV infection.
The following method was employed to detect viral RNA circulating in plasma or present in liver biopsy tissue collected from the chimpanzees.
cPCR Method to Detect HCV RNA in Liver and in Serum In the cPCR assay, putative viral RNA in the sample is reverse transcribed into cDNA with reverse l0 transcriptase; a segment of the resulting cDNA is then amplified utilizing a modified version of the PCR
technique described by Saiki et al. (1986). The primers for the cPCR technique are derived from HCV RNA, which can be identified by the family of HCV cDNAs provided herein. Amplified product corresponding to the HCV-RNA
is detected utilizing a probe derived from the family of HCV cDNAs provided herein.
The cPCR/IiCV assay used in these studies was performed utilizing the following methods for the 2o preparation of RNA, the reverse transcription of the RNA
into cDNA, the amplification of specific ssgments of the cDNA by PCR, and the analysis of the PCR products.
RNA was extracted from liver utilizing the guanidium isothiocyanate method for preparing total RNA
described in Manfatis et al. (198Z).
In order to isolate total RNA frog plasma, the plasma was diluted five- to tan-fold with TENS (0.1 M
NaCl, 50 mM Tris-HC1, pH 8.0, 1 aM EDTA) and incubated in a Proteinase K/SDS solution (0.5= SDS, 1 mg/ml Proteinase K, 20 micrograms/al Poly A carrier) for 60 to 90 minutes at 37oC. The samples ware extracted once with phenol (pH
6.5), the resulting organic phase was re-extracted once with TENB containing 0.1= SDS, and the aqueous phases of both extraction: were pooled and sxtractsd twice with an equal volume of phanol/CAC13/isoamyl alcohol [1:1(99:1)].

The resulting aqueous phases were extracted with an equal volume of ChCl3/isoamyl alcohol (99:1) twice, and ethanol precipitated using 0.2 M sodium acetate, pH 6.5, and 2.5 volumes of 100 ethanol; precipitation was overnight at -20°C.
The cDNA used as a template for the PCR re-action was prepared utilizing the designated samples for preparation of the corresponding cDNAs. Each RNA sample (containing either 2 micrograms of heat denatured total chimpanzee liver RNA or RNA from.Z microliters of plasma) was incubated in a 25 microljlter reaction containing 1 micromolar of each primer, 1 millimolar of each deoxyribonucleotide triphosphate (dNTP), 50 millimolar Tris-HCL, pH 8.3, 5 millimolar MgCl2, 5 millimolar dithiothreitol (DTT), 73 mil:limolar KC1, 40 units of RNase inhibitor (RNASIN), and 5 units of AMV reverse transcriptase. Ths incubation was for 60 minutes at 37°C. Following cDNA synthesis, the r:actions were diluted with 50 microliters of deionized water (Dlit), boiled for ifl minutes, and cooled on ice.
Amplification of a segment of the HCV cDNA was performed utilizing two synthetic oligomer 16-mer primers whose sequences ware derived from HCV cDNA clones 36 (anti-sense) and 37b (sense). The sequence of the primer from clone 36 was:

5' GG TGT GZ' GAT GTA T 3' .
The sequence of the primer from clone 37b was:
5' AG ATA CG9' GTG TG C 3' .
The primers were used at a final concentration of 1 micromolar each. In order to amplify the segment of HCV
cDNA which is flanked by the priasrs, the cONA ramples were incubated with 0.1 aicrograa of RNAse A and the PCR
reactants of the Perkin Elaer Cstus PCR kit*(N801-0043 or N801-0055) according to the manufacturer's instructions.
trad~nark iA

6 2116 7 6 4 P~/~~S92/07683 The PCR reaction was performed for either 30 cycles or 60 cycles in a Perkin Elmer Cetus DNA thermal cycler. Each cycle consisted of a 1 minute denaturation step at 94oC, an annealing step of 2 minutes at 37°C, and an extension step of 3 minutes at 72oC. However, the extension step in the final cycle (30 or 60;1 was 7 minutes rather than 3 minutes: After amplification the samples were extracted with an equal volume of phenol: chloroform (1:1), followed by extraction with .an equal volume of chloroform, and then the samples were preecipitated with ethanol containing 0.2 M sodium acetate.
The cPCR products were analyzed as follows.
The products were subjected to electrophoresis on 1.88 alkaline agarose gels according to Murakawa et al.
(1988), and transferred onto ZETAe Probe paper (BioRad Corp.) by blotting gels overnight in 0.4 M NaOH. The blots ware neutralized in 2 X SSC (1 X.SSC contains 0.15 M NaCl, 0.015 M sodium citratn~, prehybridized in 0.3 M
NaCl, 15 mM :odium phosphate buffer, pH 6.8, 15 mM EDTA, 1.08 SDS, 0.58 nonfat milk (Carnation Co.), and 0.5 mg/ml sonicated denatured salmon sperm DNA. The blots to be analyzed for HCV cDNA fragments ware hybridized to a 32P-labeled probe generated by nick translation of the HCV cDNA insert sequence in clone 35, described in U.S.S.N. 07/456,637. After hybridization, the blots were washed in 0.1 X SSC (1 X SSC: contains 0.15M NaCl, O.O1M
Na citrate) at 65oC, dried, and autoradiographed. The expected product size is 58Ei nucleotides in lsngth;
products which hybridized with the probe and migrated in 3o the gals in this size range ware scored as positive for viral RNA.
As a control, cPClt primers dssigned to amplify alpha-1 anti-trypsin sRNA was performed to verify the presence of RNA in each sample analyzed. The coding region of the alpha-1 anti-trypsin gene is described in w'O 93/06126 i 6' "~ ~' 4 P['3'/L'S92/076g3 -E~5-Rosenberg et al. (1984). Synthetic oligomer 16-mer prim-ers designed to amplify a 36:5 nucleotide fragment of the coding region of the alpha-1 antitrypsin gene were derived from nucleotides 22-:37 (sense) and nucleotides 372-387 (antisanse). The PCIt products were detected using a 32P nick-translated probe which lies between, and not including, the cDNA/PCR primer sequences.
Due to the extreme sensitivity of the PCR re-action, all samples were run a minimum of three times.
to All false positive signals were eliminated when the fol-lowing precautions were taken: 1) eliminating aerosols by using screw capped tubes with rubber O-ring seals; 2) pipetting with Ranin MICROMANe positive displacement pipetters with disposable pistons/capillaries; and 3) selecting the oligonucleotide sequences for the cDNA and PCR primers from two non-contiguous cDNA clones.
Industrial Utility The i~unorsactivs compositions of the invention, have utility in the preparation of materials, for example, vaccines, which in turn may be used for the treatment of individuals against HCV infections, particularly chronic HCV infections. In addition, the compositions may be used to prepare materials for the detection of multiple variant,a of HCV in biological samples. For example, the immunoreactive compositions of the present invention can be used to generate polyclonal antibody compositions that recognize yore than one HCV
isolate, or as the antigen in an anti-HCV antibody immunoassay. The latter method can be used to screen blood products for possible HCV contamination.
Polyclonal antiserum or antibodies can be used to for passive iamunization of an individual.

Claims (18)

1. An immunogenic polypeptide composition comprising at least two HCV amino acid sequences, each HCV sequence comprising at least one epitope within a variable domain of an HCV envelope protein, wherein the variable domain regions of the amino acid sequences are heterogeneous with each other and are derived from distinct HCV
isolates.

2. An immunogenic composition according to claim 1 comprising a plurality of antigen sets, wherein (a) each antigen set consists of a plurality of substantially identical sequences comprising at least one epitope within a variable domain of an HCV polypeptide, and (b) the amino acid sequence of the epitope of one set is heterogeneous with respect to t:he amino acid sequence of at least one other set.

3. An immunogenic composition according to claim 1 or 2 wherein the distinct HCV isolates include an HCV group I
isolate and an HCV group II isolate.

4. An immunogenic composition according to any one of claims 1 to 3 wherein the variable domain is within the E2/NS1 protein.

5. An immunogenic composition according to claim 4 wherein the variable domain is encoded from about amino acid 384 to about amino acid 414 of the HCV polyprotein of Figure 9.

6. An immunogenic composition according to any one of claims 1 to 3 wherein the variable domain is within the E1 protein.

7. An immunogenic composition according to claim 6 wherein the variable domain is encoded from about amino acid 215 to about acid 255 of the HCV polyprotein of Figure 9.

8. An immunogenic composition according to any one of claims 1 to 3 wherein each amino acid sequence further comprises an epitope within a second variable domain of an HCV polypeptide, wherein the second variable domain regions of the amino acid sequences are heterogeneous with each other and are derived from distinct HCV
isolates.

9. An immunogenic composition according to claim 8 wherein the first variable domain is within the E2/NS1 protein and second variable domain is within the E1 protein.

10. A method for preparing an immunogenic composition for treatment of HCV comprising mixing an immunogenic composition with a suitable excipient characterized in that said immunogenic composition is as defined in any one of claims 1 to 9.

11. A method for producing anti-HCV antibodies comprising (i) using an effective amount of an immunogenic composition according to any one of claims 1 to 9 in a mammal; and (ii) optionally purifying said antibodies from the blood of said mammal.

12. A polyclonal antibody composition made according to the method of claim 11.

13. A method of detecting antibodies to HCV within a biological sample comprising:

(a) providing a biological sample suspected of containing antibodies to multiple strains of HCV;
(b) providing a polypeptide reagent;
(c) reacting the biological sample of (a) with the polypeptide reagent of (b) under conditions which allow the formation of antigen-antibody complexes; and (d) detecting the formation of complexes formed between the antigen of (a) and the antibodies of the biological sample of (b), if any;
characterized in that as a polypeptide reagent it contains a immunoreactive composition according to any one of claims 1 to 9.

14. A kit for detecting antibodies to multiple strains of HCV within a biological sample comprising a diagnostic reagent and suitable packaging characterized in that as a diagnostic reagent it contains an immunoreactive composition according to any one of claims 1 to 9.

15. A DNA molecule encoding a polypeptide comprising two antigenic heterogeneous amino acid sequences from the same variable domain of distinct HCV isolates, wherein the variable domain is selected from the group consisting of the E1 or E2/NS1 domains.

16. A host cell comprising a DNA molecule according to claim 15.

17. A host cell according to claim 16 wherein the DNA
molecule comprises control sequences that are capable of causing the expression of the polypeptide.

18. A method of making a recombinant protein comprising growing a population of host cells according to claim 17 under conditions that provide for the expression of the polypeptide.